drugset / Trial / NCT07125950

SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

NCT07125950

Phase 2 Not yet recruiting 60 enrolled Henan Cancer Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Our study is aimed to evaluate the safety and preliminary of all-oral regimen SHR2554 combined with HRS-8080 or HRS-1358 in advanced breast cancer.

Timeline

Start
2025-09-30
Primary completion
2027-09-30
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-1358 Unknown
Subject HRS-8080 Unknown
Subject SHR2554 Small molecule

Indications